Meeting
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
Authors
Gargi D. Basu
Ashion Analytics, Phoenix, AZ
Gargi D. Basu , Tracey White , Janine R LoBello , Ahmet Kurdoglu , Jeffrey M. Trent , Matthew J Halbert , Thomas Royce , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1040)
DOI
10.1200/JCO.2017.35.15_suppl.1040
Abstract #
1040
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Poster
2015 ASCO Annual Meeting
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
First Author: Payal Deepak Shah
Poster
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
First Author: William John Gradishar
Poster
2012 ASCO Annual Meeting
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
First Author: Mothaffar F. Rimawi